Bluebird Exits Europe, Casting Clouds Over Gene Therapy Commercial Effort
The company will prioritize US market for gene therapies; FDA also placed eli-cel for CALD on clinical hold following a case of MDS.
You may also be interested in...
Public Company Edition: Blade will merge with a special purpose acquisition corporation to go public, Bluebird spins out 2seventy with $442m in cash and Compass raises $125m in a move to the Nasdaq.
The formal split between the companies had been in the works since January, with 2seventy set to take over oncology operations while bluebird focuses on gene therapies.
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.